NCAPH is negatively associated with Mcl‑1 in non‑small cell lung cancer

Abstract

lung cancer has a high mortality rate worldwide. non-SMc condensin i complex subunit H (ncaPH) has been identified to be one of the regulatory subunits of the condensin i complex, which is essential for the correct packaging and segregation of chromosomes in eukaryotes. NCAPH is abnormally overexpressed in various types of cancer. a pro-survival member of the Bcl-2 family, myeloid cell leukemia sequence 1 (Mcl-1) is also frequently overexpressed in multiple cancers and is associated with poorer clinical outcomes for patients. The association of NCAPH and Mcl-1 proteins with the clinical and pathological features of non-small cell lung cancer (NSCLC) remains to be elucidated. In the current study, the positive percentage of ncaPH in the non-cancerous lung tissues was revealed to be higher compared with that in nSclc. However, the positive percentage of Mcl-1 in the non-cancerous lung tissues was lower compared with nSclc. in addition, ncaPH high-expression patients had a higher overall survival rate compared with patients exhibiting low expression, whereas the Mcl-1 high-expression group had a lower survival rate. Pairwise association in 260 cases of NSCLC revealed that overexpression of the NCAPH protein was negatively associated with Mcl-1 expression and vice versa. The results of multivariate Cox proportional hazard regression analysis also indicated that ncaPH and Mcl-1 demonstrated potential as distinct prognostic factors that may be used in NSCLC. The expression of NCAPH and Mcl-1 may be associated with, and act as distinct molecular marks for the prediction of a poor prognosis in patients with nSclc.

NCAPH promotes proliferation as well as motility of breast cancer cells by activating the PI3K/AKT pathway

“…Another study indicated that NCAPH mediated the progression of gastric cancer via affecting DNA damage response [10]. NCAPH was negatively correlated with Mcl-1 expression in lung cancer [20]. Importantly, another study showed that NCAPH was required for the viability and motility of lung cancer cells, similar to our study [12].…”

Association of NCAP family genes with prognosis and immune infiltration of human sarcoma

“…Similarly, NCAPH can be used as a prognostic biomarker for non-small cell lung cancer, lung adenocarcinoma, nasopharyngeal carcinoma, breast cancer, and hepatocellular carcinoma [22][23][24][25][26]. In addition, Meng Wang et al found that NCAPH regulated the occurrence of cervical cancer through the PI3K/AKT/SGK pathway [27].…”

Screening of Potential Key Biomarkers for Ewing Sarcoma: Evidence from Gene Array Analysis

“…67 The expression of NCAPH and Mcl-1 suggests that patients with non-small cell lung cancer may have a poor prognosis. 68 Many NCAPH mutations have been found in patients with colon cancer. 69 In summary, this study aims to screen and identify DEGs that may be involved in the carcinogenesis or progression of ES.…”